Literature DB >> 6815740

Serum binding of tocainide and its enantiomers in human subjects.

A J Sedman, D C Bloedow, J Gal.   

Abstract

Serum from five healthy male volunteers aged 25-36 years was dialyzed against a series of buffer solutions containing varying amounts of racemic tocainide. The concentration of each enantiomer of the drug in the post-dialysis buffer and serum was determined using a specific gas-liquid-chromatographic method. The concentration of total tocainide in the post-dialysis sera ranged from 1.16 to 19.73 micrograms/ml. The percentage of total unbound tocainide ranged from 84.9 +/- 3.3 to 89.9 +/- 2.2 (mean +/- S.D.) whereas the percentages of unbound R-(-) and S-(+) enantiomers ranged from 86.3 +/- 4.0 to 91.0 +/- 2.3 and 83.3 +/- 5.4 to 88.9 +/- 2.2 respectively. Although the binding of the S-(+) enantiomer was slightly but statistically significantly greater than that of the R-(-) isomer, the difference would be of little clinical significance. Binding appeared independent of serum tocainide concentration within the therapeutic range of 4 to 12 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6815740

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  6 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.

Authors:  A H Thomson; G Murdoch; A Pottage; A W Kelman; B Whiting; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 4.  Serum tocainide enantiomer concentrations in human subjects.

Authors:  A J Sedman; J Gal; W Mastropaolo; P Johnson; J D Maloney; T P Moyer
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

5.  Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects.

Authors:  K M McErlane; J Axelson; R Vaughan; C R Kerr; J D Price; L Igwemezie; G Pillai
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.